Pierre Wolkenstein Selected Research

Neurofibromatoses (Neurofibromatosis)

1/2022	Treatment of cutaneous neurofibromas with carbon dioxide laser: Technique and patient experience.
1/2019	Absence of Efficacy of Everolimus in Neurofibromatosis 1-Related Plexiform Neurofibromas: Results from a Phase 2a Trial.
1/2019	First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
10/2018	Creating a comprehensive research strategy for cutaneous neurofibromas.
8/2016	Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
4/2016	Low Rates of Blood Transfusion in Elective Resections of Neurofibromas in a Cohort Study: Neurofibroma Length as a Predictor of Transfusion Requirement.
1/2016	Metabolic Tumour Burden Measured by 18F-FDG PET/CT Predicts Malignant Transformation in Patients with Neurofibromatosis Type-1.
1/2015	Treatment of neurofibromas with a carbon dioxide laser: a retrospective cross-sectional study of 106 patients.
12/2014	Treatment of sphenoid dysplasia with a titanium-reinforced porous polyethylene implant in orbitofrontal neurofibroma: report of three cases.
1/2010	Differential expression of CCN1/CYR61, CCN3/NOV, CCN4/WISP1, and CCN5/WISP2 in neurofibromatosis type 1 tumorigenesis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pierre Wolkenstein Research Topics

Disease

20	Neoplasms (Cancer) 10/2022 - 12/2003
16	Plexiform Neurofibroma 10/2022 - 12/2003
12	Neurofibroma 10/2022 - 12/2003
12	Neurofibromatoses (Neurofibromatosis) 01/2022 - 09/2003
11	Neurofibromatosis 1 (Neurofibromatosis Type I) 11/2021 - 12/2003
8	Neurofibrosarcoma (MPNST) 10/2022 - 06/2004
8	Stevens-Johnson Syndrome (Lyell's Syndrome) 01/2018 - 11/2004
5	Neurofibromatosis 2 (Neurofibromatosis Type II) 01/2022 - 12/2003
5	Pain (Aches) 01/2022 - 06/2009
4	Carcinogenesis 10/2022 - 01/2007
4	Schwannomatosis 01/2022 - 12/2003
4	Melanoma (Melanoma, Malignant) 12/2015 - 10/2006
3	Acute Generalized Exanthematous Pustulosis 04/2021 - 10/2017
3	Blister (Bulla) 05/2017 - 11/2004
2	Drug Eruptions (Drug Eruption) 05/2022 - 07/2002
2	Skin Neoplasms (Skin Cancer) 01/2022 - 12/2009
2	Acoustic Neuroma (Acoustic Neurinoma) 11/2021 - 04/2014
2	Glioma (Gliomas) 11/2021 - 01/2007
2	Bullous Pemphigoid (Pemphigoid) 02/2021 - 01/2015
2	Infections 10/2018 - 10/2016
2	Cicatrix (Scar) 10/2017 - 08/2015
2	Eosinophilia 10/2017 - 01/2008
2	Pemphigus (Pemphigus Vulgaris) 02/2015 - 01/2014
2	Neurilemmoma (Schwannoma) 04/2014 - 12/2003
2	Exanthema (Rash) 09/2012 - 01/2008
2	Acquired Immunodeficiency Syndrome (AIDS) 11/2005 - 07/2002
1	Autoimmune Diseases (Autoimmune Disease) 01/2022
1	Embolism and Thrombosis 01/2022
1	Human Influenza (Influenza) 01/2022
1	Meningioma (Meningiomas) 11/2021
1	Metabolic Bone Diseases (Osteopenia) 01/2021
1	Secondary Hyperparathyroidism 01/2021
1	Vitamin D Deficiency 01/2021
1	Angiofibroma 01/2020
1	Tuberous Sclerosis (Bourneville's Disease) 01/2020
1	Hidradenitis Suppurativa 11/2019
1	Hypersensitivity (Allergy) 06/2019
1	Rare Diseases (Rare Disease) 10/2018
1	Agranulocytosis (Granulocytopenia) 01/2018
1	Inflammation (Inflammations) 01/2018
1	Acute Kidney Injury (Acute Renal Failure) 01/2018
1	Autoimmune Lymphoproliferative Syndrome 01/2018
1	Contact Dermatitis (Eczema, Contact) 01/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2018
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2018
1	Erythema Multiforme 01/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	Drug-Related Side Effects and Adverse Reactions 11/2017

Drug/Important Bio-Agent (IBA)

14	Pharmaceutical PreparationsIBA 05/2022 - 07/2002
8	Proteins (Proteins, Gene)FDA Link 10/2022 - 12/2003
4	Sirolimus (Rapamycin)FDA Link 01/2020 - 04/2014
3	Uvitex SWN (SWN)IBA 01/2022 - 08/2016
3	CytokinesIBA 01/2019 - 06/2004
3	Messenger RNA (mRNA)IBA 03/2011 - 06/2004
3	AntibodiesIBA 02/2010 - 12/2003
2	Thalidomide (Thalomid)FDA Link 11/2019 - 01/2018
2	Mechanistic Target of Rapamycin Complex 1IBA 06/2016 - 04/2014
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2016 - 01/2014
2	Rituximab (Mabthera)FDA Link 02/2015 - 02/2010
2	Adrenal Cortex Hormones (Corticosteroids)IBA 02/2015 - 07/2002
2	TOR Serine-Threonine KinasesIBA 06/2014 - 04/2014
2	Analgesics (Analgesic Drugs)IBA 06/2014 - 06/2009
2	EnzymesIBA 01/2014 - 11/2005
2	MicroRNAs (MicroRNA)IBA 07/2013 - 01/2011
2	Neurofibromin 1 (Neurofibromin)IBA 09/2011 - 04/2004
2	Transcription Factors (Transcription Factor)IBA 03/2011 - 06/2004
2	SulfonamidesIBA 11/2005 - 07/2002
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2022
1	baricitinibIBA 01/2022
1	ruxolitinibIBA 01/2022
1	tofacitinibIBA 01/2022
1	Janus Kinase InhibitorsIBA 01/2022
1	Janus KinasesIBA 01/2022
1	Enoxaparin (Lovenox)FDA LinkGeneric 04/2021
1	Volatile Oils (Essential Oils)IBA 02/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	Phosphorus (Red Phosphorus)IBA 01/2021
1	CalciumIBA 01/2021
1	Petrolatum (Vaseline)FDA Link 01/2020
1	Mupirocin (Bactroban)FDA LinkGeneric 06/2019
1	Everolimus FDA Link 01/2019
1	thymoquinoneIBA 01/2018
1	4-cymene (p-cymene)IBA 01/2018
1	Nigella sativa oilIBA 01/2018
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2018
1	Lenalidomide (CC 5013)FDA Link 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2017
1	Interleukin-15 (Interleukin 15)IBA 05/2017

Therapy/Procedure

11	Therapeutics 01/2022 - 01/2007
4	Lasers (Laser) 01/2022 - 09/2011
3	Aftercare (After-Treatment) 10/2018 - 01/2015
2	Gas Lasers 01/2022 - 01/2015
2	Transplantation 01/2019 - 10/2016
2	Surgical Amputation (Amputations) 08/2013 - 06/2009
1	Drug Tapering 01/2019
1	Critical Care (Surgical Intensive Care) 10/2018
1	Mediterranean Diet 01/2018
1	Combination Drug Therapy (Combination Chemotherapy) 01/2018